NA-Semax-Amidate

NA-Semax-Amidate represents an optimized form of the nootropic peptide Semax, incorporating both N-terminal acetylation and C-terminal amidation modifications. These structural changes enhance the peptide's resistance to enzymatic degradation, potentially extending its duration of action and improving CNS bioavailability.

The N-acetyl modification protects against aminopeptidases that would otherwise cleave the N-terminal methionine, while the C-terminal amide provides resistance to carboxypeptidases. Together, these modifications create a more stable molecule that may achieve higher brain concentrations following intranasal administration.

The parent compound Semax is a well-characterized nootropic that enhances BDNF and NGF expression, modulates monoamine neurotransmission, and demonstrates neuroprotective properties. NA-Semax-Amidate is hypothesized to produce similar or enhanced effects due to its improved pharmacokinetic profile, though direct comparative research is still emerging.

This modified form has gained interest in the nootropic research community for applications requiring sustained cognitive enhancement or where the standard Semax's relatively short half-life presents limitations. The combination of proven mechanism with enhanced stability makes it an attractive research tool for studying peptide-based cognitive enhancement.